XML 74 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Earnings Per Share
9 Months Ended
Sep. 30, 2014
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
 
Vested restricted stock units issued under the Company’s stock-based compensation plans participate in a cash equivalent of the dividends paid to common stockholders and are not considered contingently issuable shares. Accordingly, these RSUs are included in the calculation of basic and diluted earnings per share as common stock equivalents. RSUs that have not vested and are subject to a risk of forfeiture are included solely in the calculation of diluted earnings per share.

The components of basic and diluted earnings per share are as follows:
 
Three months ended
Nine months ended
(In thousands)
September 30, 2014
September 30, 2013
September 30, 2014
September 30, 2013
Net earnings (loss) attributable to Blyth, Inc.
$
106,173

$
(8,470
)
$
98,972

$
(7,232
)
Weighted average number outstanding:
 
 
 
 
Common shares
16,055

16,013

16,041

16,182

Vested restricted stock units
71

58

64

55

Weighted average number of common shares outstanding:
 
 
 
 
Basic common shares outstanding
16,126

16,071

16,105

16,237

Dilutive effect of non-vested restricted shares units
42


47


Diluted common shares outstanding
16,168

16,071

16,152

16,237

Basic earnings per share
 
 
 
 
Net loss from continuing operations
$
(0.59
)
$
(0.57
)
$
(0.80
)
$
(0.85
)
Net earnings from discontinued operations
7.17

0.04

6.95

0.40

Net earnings (loss) attributable to Blyth, Inc.
$
6.58

$
(0.53
)
$
6.15

$
(0.45
)
Diluted earnings per share
 
 
 

 

Net loss from continuing operations
$
(0.59
)
$
(0.57
)
$
(0.80
)
$
(0.85
)
Net earnings from discontinued operations
7.16

0.04

6.93

0.40

Net earnings (loss) attributable to Blyth, Inc.
$
6.57

$
(0.53
)
$
6.13

$
(0.45
)

 
As of September 30, 2013, options to purchase 2,500 shares of common stock, respectively, are not included in the computation of diluted earnings per share because the effect would be antidilutive.